Search Results

You are looking at 31 - 40 of 512 items for :

  • User-accessible content x
Clear All
Free access

Jun-ichi Eiki, Kaori Saeki, Norihiro Nagano, Tomoharu Iino, Mari Yonemoto, Yoko Takayenoki-Iino, Satoru Ito, Teruyuki Nishimura, Yoshiyuki Sato, Makoto Bamba, Hitomi Watanabe, Kaori Sasaki, Sumika Ohyama, Akio Kanatani, Toshio Nagase and Toshihiko Yada

Introduction Glucagon-like peptide-1 (GLP-1) is a hormone secreted from enteroendocrine L-cells, and is well recognized as an incretin that induces insulin secretion in a glucose-dependent manner ( Drucker 2006 ). The functions of GLP-1 have been

Free access

Can Liu, Mian Zhang, Meng-yue Hu, Hai-fang Guo, Jia Li, Yun-li Yu, Shi Jin, Xin-ting Wang, Li Liu and Xiao-dong Liu

, it is noteworthy that local high concentration of ginsenosides in intestine may interact with intestinal epithelium, where numerous endocrine cells are located. Glucagon-like peptide-1 (GLP1), secreted by enteroendocrine L-cells, is one of the most

Free access

Mi-Hyun Kim, Jae-Hwan Jee, Sunyoung Park, Myung-Shik Lee, Kwang-Won Kim and Moon-Kyu Lee

Introduction Glucagon-like peptide (GLP)-1 is an intestinal hormone that exerts its effects in the regulation of glucose metabolism, the stimulation of pancreatic insulin secretion, proinsulin gene expression, and the proliferation and anti

Free access

Li Zhao, Chunfang Zhu, Meng Lu, Chi Chen, Xiaomin Nie, Buatikamu Abudukerimu, Kun Zhang, Zhiyuan Ning, Yi Chen, Jing Cheng, Fangzhen Xia, Ningjian Wang, Michael D Jensen and Yingli Lu

. 2010 ). Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by gastrointestinal L cells in response to oral nutrient ingestion ( Wan et al . 2017 ) and is an ideal therapy for obesity and T2DM ( Rajeev & Wilding 2016 ). However, native

Free access

R A Silvestre, E M Egido, R Hernández and J Marco

kisspeptin-13 on insulin, glucagon, and somatostatin secretion. The study was performed in the isolated perfused rat pancreas. Animals, materials, and methods Animals Male Wistar rats (200–225 g body weight) from our inbred colony were used as

Free access

Hongbin Liu, Anthony E Dear, Lotte B Knudsen and Richard W Simpson

protected from the development of biochemical abnormalities associated with endothelial cell dysfunction and development of atherosclerosis ( Eitzman et al . 2000 , Mao et al . 2004 ). Liraglutide, an acylated glucagon-like peptide-1 (GLP-1) analogue, has

Free access

Hongbin Liu, Yunshan Hu, Richard W Simpson and Anthony E Dear

Introduction Glucagon-like peptide-1 (GLP-1), an incretin first identified in 1984, has been proposed as a potential candidate target for therapy in the treatment of type 2 diabetes ( Nauck et al . 1993 , Edwards 2005 ). GLP-1, the product of the

Free access

Patrice D Cani, Catherine A Daubioul, Brigitte Reusens, Claude Remacle, Grégory Catillon and Nathalie M Delzenne

( Reimer & McBurney 1996 , Cani et al. 2004 ). In the intestine, the post-translational modification of the proglucagon gene by prohormone convertase 1 (PC1) leads to the production of glucagon-like peptide-1(7–36) amide (GLP-1(7–36) amide) which, among

Free access

L Bai, G Meredith and B E Tuch

Introduction Glucagon-like peptide-1 (GLP-1) is a peptide secreted from the gut in response to food. It acts directly on β cells, enhancing the effect of glucose in stimulating insulin secretion from these cells. When administered to

Free access

Neville H McClenaghan, Peter R Flatt and Andrew J Ball

-cell desensitisation compared with sulphonylureas may occur following prolonged exposure to nateglinide ( Ball et al. 2004 b ). In vivo , insulin secretion can be stimulated by glucagon-like peptide-1 (GLP-1), a hormone of the enteroinsular axis, released